Logo
x

Search

Subscribe Now

GSK

GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer

GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer

  • December 20, 2024
GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

  • December 19, 2024
ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment

ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment

  • December 18, 2024
GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer

GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer

  • December 17, 2024
GSK’s Jemperli (dostarlimab) Secures the US FDA’s Breakthrough Therapy Designation to Treat Rectal Cancer

GSK’s Jemperli (dostarlimab) Secures the US FDA’s Breakthrough Therapy Designation to Treat Rectal Cancer

  • December 16, 2024
GSK Reports the US FDA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

GSK Reports the US FDA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

  • December 9, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.